• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

西洛他唑治疗间歇性跛行的安全性和有效性。

Safety and efficacy of cilostazol in the management of intermittent claudication.

作者信息

Chi Yung-Wei, Lavie Carl J, Milani Richard V, White Christopher J

机构信息

Department of Cardiology, Section of Vascular Medicine, Ochsner Health System, 2005 Veterans Blvd., Metairie, LA 70002, USA.

出版信息

Vasc Health Risk Manag. 2008;4(6):1197-203. doi: 10.2147/vhrm.s3160.

DOI:10.2147/vhrm.s3160
PMID:19337533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2663440/
Abstract

Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

摘要

外周动脉疾病（PAD）是一个影响全球数百万患者的主要健康问题。许多患者会出现间歇性跛行（IC），这会导致生活质量（QoL）显著受损。除了通过手术和血管内介入治疗来改善肢体特定结局外，药物治疗是治疗IC的有效手段。西洛他唑是一种经美国食品药品监督管理局批准用于治疗IC的药物，在改善运动能力和整体健康相关生活质量方面已显示出持续的疗效。本文将综述西洛他唑治疗IC患者的药代动力学、安全性和疗效，并将该药物与其他已证实的PAD非侵入性治疗方法进行比较。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/9b014e096749/vhrm-4-1197f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/d4538238a909/vhrm-4-1197f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/a296f5e19b6c/vhrm-4-1197f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/48c6152d2795/vhrm-4-1197f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/40af18aa7302/vhrm-4-1197f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/9b014e096749/vhrm-4-1197f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/d4538238a909/vhrm-4-1197f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/a296f5e19b6c/vhrm-4-1197f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/48c6152d2795/vhrm-4-1197f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/40af18aa7302/vhrm-4-1197f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a68/2663440/9b014e096749/vhrm-4-1197f5.jpg

相似文献

1
Safety and efficacy of cilostazol in the management of intermittent claudication.西洛他唑治疗间歇性跛行的安全性和有效性。
Vasc Health Risk Manag. 2008;4(6):1197-203. doi: 10.2147/vhrm.s3160.
2
The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.西洛他唑对糖尿病外周动脉疾病患者的血管及生化作用
Vasc Endovascular Surg. 2009 Apr-May;43(2):132-43. doi: 10.1177/1538574408328586. Epub 2009 Jan 8.
3
Cilostazol: a new drug in the treatment intermittent claudication.西洛他唑：治疗间歇性跛行的一种新药。
Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3):181-5. doi: 10.2174/157489007782418991.
4
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.西洛他唑对因外周动脉疾病导致间歇性跛行患者的跑步机行走、社区行走能力及健康相关生活质量的影响：六项随机对照试验的荟萃分析
J Am Geriatr Soc. 2002 Dec;50(12):1939-46. doi: 10.1046/j.1532-5415.2002.50604.x.
5
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.西洛他唑对周围血管疾病所致间歇性跛行患者步行距离的影响。
J Vasc Surg. 1998 Feb;27(2):267-74; discussion 274-5. doi: 10.1016/s0741-5214(98)70357-x.
6
Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.动脉粥样硬化性外周动脉疾病的临床表现及西洛他唑在治疗间歇性跛行中的作用。
J Clin Pharmacol. 2002 Dec;42(12):1291-8. doi: 10.1177/0091270002042012002.
7
Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.健康男性及因外周动脉疾病导致间歇性跛行的患者单次及多次口服西洛他唑后的药代动力学。
Clin Pharmacokinet. 1999;37 Suppl 2:1-11. doi: 10.2165/00003088-199937002-00001.
8
Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.衡量西洛他唑对间歇性跛行患者临床试验终点的治疗效果。
Clin Cardiol. 2002 Mar;25(3):91-4. doi: 10.1002/clc.4960250303.
9
Cilostazol for peripheral arterial disease.西洛他唑用于治疗外周动脉疾病。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003748. doi: 10.1002/14651858.CD003748.pub2.
10
Cilostazol for peripheral arterial disease.西洛他唑用于治疗外周动脉疾病。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003748. doi: 10.1002/14651858.CD003748.pub3.

引用本文的文献

1
Cilostazol protects against gastric ulcers by regulating PPAR-γ, HO-1, PECAM-1, pErk-1, NF-κB, Bcl-2, and cleaved caspase-3 protein expression.西洛他唑通过调节 PPAR-γ、HO-1、PECAM-1、pErk-1、NF-κB、Bcl-2 和 cleaved caspase-3 蛋白表达来预防胃溃疡。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):9033-9050. doi: 10.1007/s00210-024-03176-7. Epub 2024 Jun 17.
2
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.在人肺细胞中发现瑞德西韦与已批准药物的 SARS-CoV-2 抗病毒协同作用。
Sci Rep. 2022 Nov 2;12(1):18506. doi: 10.1038/s41598-022-21034-5.
3

本文引用的文献

1
Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.阿司匹林与西洛他唑联合治疗可降低血小板聚集，并预防运动诱导的血小板活化。
Eur J Vasc Endovasc Surg. 2009 May;37(5):604-10. doi: 10.1016/j.ejvs.2009.01.008. Epub 2009 Mar 17.
2
Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.西洛他唑可改善接受经皮腔内血管成形术的外周动脉疾病血液透析患者的长期血管通畅率。
Clin J Am Soc Nephrol. 2008 Jul;3(4):1034-40. doi: 10.2215/CJN.05761207. Epub 2008 Mar 5.
3
Pathophysiology of chronic peripheral ischemia: new perspectives.
慢性周围性缺血的病理生理学：新观点
Ther Adv Chronic Dis. 2020 Feb 5;11:2040622319894466. doi: 10.1177/2040622319894466. eCollection 2020.
4
Population pharmacodynamics of cilostazol in healthy Korean subjects.西洛他唑在健康韩国受试者中的群体药效学。
Transl Clin Pharmacol. 2018 Jun;26(2):93-98. doi: 10.12793/tcp.2018.26.2.93. Epub 2018 Jun 18.
5
Gastroprotective effect of cilostazol against ethanol- and pylorus ligation-induced gastric lesions in rats.西洛他唑对乙醇和幽门结扎致大鼠胃损伤的胃保护作用。
Naunyn Schmiedebergs Arch Pharmacol. 2019 Dec;392(12):1605-1616. doi: 10.1007/s00210-019-01699-y. Epub 2019 Aug 1.
6
Antithrombotic therapy in ventricular assist device (VAD) management: From ancient beliefs to updated evidence. A narrative review.心室辅助装置（VAD）管理中的抗栓治疗：从古老信念到最新证据。一项叙述性综述。
Int J Cardiol Heart Vasc. 2018 Jun 30;20:20-26. doi: 10.1016/j.ijcha.2018.06.005. eCollection 2018 Sep.
7
Formulation of cilostazol spherical agglomerates by crystallo-co-agglomeration technique and optimization using design of experimentation.通过结晶共附聚技术制备西洛他唑球形附聚物并采用实验设计进行优化。
Int J Pharm Investig. 2017 Oct-Dec;7(4):164-173. doi: 10.4103/jphi.JPHI_39_17.
8
Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support.常规临床抗血小板药物在调节与机械循环支持相关的高剪切介导的血小板激活方面效果有限。
Thromb Res. 2018 Mar;163:162-171. doi: 10.1016/j.thromres.2017.12.001. Epub 2017 Dec 5.
9
Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.西洛他唑的使用与痴呆风险降低相关：一项全国性队列研究。
Neurotherapeutics. 2017 Jul;14(3):784-791. doi: 10.1007/s13311-017-0512-4.
10
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.短暂性脑缺血发作和缺血性卒中长期二级预防中的抗血小板治疗方案：一项更新的网状Meta分析
BMJ Open. 2016 Mar 17;6(3):e009013. doi: 10.1136/bmjopen-2015-009013.
Cilostazol: a new drug in the treatment intermittent claudication.
西洛他唑：治疗间歇性跛行的一种新药。
Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3):181-5. doi: 10.2174/157489007782418991.
4
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.药物洗脱支架置入术后西洛他唑与氯吡格雷在糖尿病患者中的随机对照研究——药物洗脱支架治疗糖尿病患者的西洛他唑（CIDES）试验
Circ J. 2008 Jan;72(1):35-9. doi: 10.1253/circj.72.35.
5
The role of exercise training in peripheral arterial disease.运动训练在外周动脉疾病中的作用。
Vasc Med. 2007 Nov;12(4):351-8. doi: 10.1177/1358863X07083177.
6
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.他汀类药物与西洛他唑联合使用的心脏保护作用：与Akt及内皮型一氧化氮合酶激活的关系。
Cardiovasc Drugs Ther. 2007 Oct;21(5):321-30. doi: 10.1007/s10557-007-6036-0.
7
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.西洛他唑可减轻高血压合并2型糖尿病患者的炎症负担和氧化应激。
Pharmacol Res. 2007 Aug;56(2):118-23. doi: 10.1016/j.phrs.2007.04.007. Epub 2007 May 3.
8
Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism.西洛他唑通过环磷酸腺苷/蛋白激酶A和磷脂酰肌醇3激酶/蛋白激酶B依赖性机制激活内皮型一氧化氮合酶。
Atherosclerosis. 2006 Dec;189(2):350-7. doi: 10.1016/j.atherosclerosis.2006.01.022. Epub 2006 Mar 20.
9
The US experience with cilostazol in treating intermittent claudication.美国使用西洛他唑治疗间歇性跛行的经验。
Atheroscler Suppl. 2005 Dec 15;6(4):21-31. doi: 10.1016/j.atherosclerosissup.2005.09.004. Epub 2005 Nov 4.
10
Coronary stent restenosis in patients treated with cilostazol.西洛他唑治疗患者的冠状动脉支架再狭窄
Circulation. 2005 Nov 1;112(18):2826-32. doi: 10.1161/CIRCULATIONAHA.104.530097. Epub 2005 Oct 24.